

# Mapi Values publications 2008–2011

ADDELPHI MAPI  
Alliance

Excellence

## Peer Reviewed Journals

Cancer .....	2
Cardiovascular diseases .....	2
Central nervous system / Mental disorders.....	2
Eye diseases .....	2
Gastrointestinal diseases .....	3
Haematologic diseases.....	3
Immune system diseases .....	4
Infections.....	4
Metabolic diseases.....	5
Musculoskeletal diseases.....	5
Nutrition.....	6
Paediatrics.....	6
Respiratory tract diseases .....	7
Skin diseases .....	7
Urogenital diseases .....	7
Womens health .....	8
Methodology .....	8

## Conference oral presentations

Cardiovascular diseases .....	9
Central nervous system / Mental disorders .....	9
Gastrointestinal diseases .....	9
Musculoskeletal diseases.....	9
Respiratory tract diseases .....	10
Urogenital diseases .....	10
Methodology .....	10

## Posters

Cancer .....	11
Cardiovascular diseases .....	12
Central nervous system / Mental disorders.....	12
Eye diseases .....	13
Gastrointestinal diseases .....	13
Infections.....	14
Metabolic diseases.....	14
Musculoskeletal diseases.....	15
Paediatrics .....	16
Respiratory tract diseases .....	17
Skin diseases .....	17
Urogenital diseases .....	18
Womens health .....	18
Methodology .....	19

## Peer Reviewed Journals

### Cancer

- Bredart A, Sultan S, Regnault A. **Patient satisfaction instruments for cancer clinical research or practice.** *Expert Rev Pharmacoecon Outcomes Res* 2010 April;10(2):129-41.
- Kitchen H, Rofail D, Caron M, et al. **Oncology patient-reported claims: maximising the chance for success.** 2011 May.
- Hahn EA, Cella D, Dobrez DG, et al. **Quality of life assessment for low literacy Latinos: a new multimedia program for self-administration.** *J Oncol Manag* 2011;12(5):9-12.
- Parthan A, Posner MR, Brammer C, et al. **Cost utility of docetaxel as induction chemotherapy followed by chemoradiation in locally advanced squamous cell carcinoma of the head and neck.** *Head Neck* 2009 Oct;31(10):1255-62.
- Trask PC, Tellefsen C, Espindle D, et al. **Psychometric validation of the Cancer Therapy Satisfaction Questionnaire.** *Value Health* 2008 July-August; 11(4):669-79.
- Vissers D, Stam W, Nolte T, et al. **Efficacy of intranasal fentanyl spray versus other opioids for breakthrough pain in cancer.** *Curr Med Res Opin* 2010 May;26(5):1037-45.

### Cardiovascular diseases

- Prins MH, Guillemin I, Gilet H, et al. **Scoring and psychometric validation of the Perception of Anticoagulant Treatment Questionnaire (PACT-Q<sup>®</sup>).** *Health Qual Life Outcomes* 2009 April 7;7(30).

### Central nervous system / Mental disorders

- Abetz L, Rofail D, Mertzanis P, et al. **Alzheimer's disease treatment: assessing caregiver preferences for mode of treatment delivery.** *Adv Ther* 2009 June;26(6):627-44.
- Arbuckle R, Frye MA, Brecher M, et al. **The psychometric validation of the Sheehan Disability Scale (SDS) in patients with bipolar disorder.** *Psychiatry Res* 2009 January 30;165(1-2):163-74.

### Eye diseases

- Baudouin C, Creuzot-Garcher C, Hoang-Xuan T, et al. **Severe impairment of health-related quality of life in patients suffering from ocular surface diseases.** *J Fr Ophthalmol* 2008 April;31(4):369-78.
- Béchettoille A, Arnould B, Bron A, et al. **Measurement of health-related quality of life with glaucoma: validation of the Glau-QoL 36-item questionnaire.** *Acta Ophthalmol* 2008 Feb;86(1):71-80.
- Berdeaux G, Meunier J, Arnould B, et al. **Measuring benefits and patients' satisfaction when glasses are not needed after cataract and presbyopia surgery: scoring and psychometric validation of the Freedom from Glasses Value Scale (FGVS<sup>®</sup>).** *BMC Ophthalmol* 2010 May;10-15.

## Peer Reviewed Journals

- Berdeaux G, Viala M, Roborel de Climens A, et al. **Patient-reported benefit of ReSTOR® multi-focal intraocular lenses after cataract surgery: results of principal component analysis on clinical trial data.** *Health Qual Life Outcomes* 2008 January 24;6:10.
- Cochener B, Arnould B, Viala M, et al. **Corrected and uncorrected near and distance vision with ReSTOR® compared to monofocal intraocular lens implantation after cataract surgery: a pooled analysis.** *Ophthalmologica* 2009;223(2):128-35.
- Cochener B, Fernández-Vega L, Maurel F, et al. **Spectacle independence and subjective satisfaction of ReSTOR® multifocal intraocular lens after cataract or presbyopia surgery in two European countries.** *Clin Ophthalmol* 2010 March 4;4:81-9.
- Lévy P, Elies D, Dithmer O, et al. **Development of a new subjective questionnaire: the Freedom from Glasses Value Scale (FGVS).** *J Refract Surg* 2010 June;26(6):438-46.
- Nordmann JP, Baudouin C, Renard JP, et al. **Identification of non-compliant glaucoma patients using Bayesian networks and the eye-drop satisfaction questionnaire.** *Clin Ophthalmol* 2010. In press.
- Regnault A, Viala-Danten M, Gilet H, et al. **Scoring and psychometric properties of the Eye-Drop Satisfaction Questionnaire (EDSQ), an instrument to assess satisfaction and compliance with glaucoma treatment.** *BMC Ophthalmol* 2010 February 1;10:1.

### Gastrointestinal diseases

- Dubois D, Gilet H, Viala-Danten M, et al. **Psychometric performance and clinical meaningfulness of the patient assessment of constipation-quality of life questionnaire in prucalopride (RESOLOR) trials for chronic constipation.** *Neurogastroenterol Motil* 2010 February;22(2):54-63.
- Marant C, Arnould B, Marrel A, et al. **Assessing patients' satisfaction with anti-TNFalpha treatment in Crohn's disease: qualitative steps of the development of a new questionnaire.** *Clin Exp Gastroenterol* 2011 July;4:173-80.
- Marant C, Arnould B, Marrel A, Spizak C, Colombel JF, Faure P, et al. **Assessing patients' satisfaction with anti-TNFalpha treatment in Crohn's disease: qualitative steps of the development of a new questionnaire.** *Clin Exp Gastroenterol.* 2011;4:173-180.

### Haematologic diseases

- Gater A, Thomson A, Strandberg-Larsen M. **Haemophilia B: impact on patients and economic burden of disease.** *Thromb Haemost* 2011 August; 106(3):398-404.
- Rofail D, Abetz L, Viala M, et al. **Satisfaction and adherence in patients with iron overload receiving iron chelation therapy as assessed by a newly developed patient instrument.** *Value Health* 2009 January; 12(1):109-17.
- Rofail D, Viala M, Gater A, et al. **An instrument assessing satisfaction with iron chelation therapy: Psychometric testing from an open-label clinical trial.** *Adv Ther* 2010 August;27(8):533-46.
- Stam WB, Aversa F, Kumar RN, et al. **Economic evaluation of caspofungin versus liposomal amphotericin B for empiric antifungal treatment in patients with neutropenic fever in Italy.** *Value Health* 2008 Sep-Oct;11(5):830-41.

## Peer Reviewed Journals

Stam WB, O'Sullivan AK, Rijnders B, et al. **Economic evaluation of posaconazole vs. standard azole prophylaxis in high risk neutropenic patients in the Netherlands.** *Eur J Haematol* 2008 Dec;81(6):467-74.

Strandberg-Larsen M, Gater A, Thomson A. **Hemophilia A: patient impact and economic burden of the disease.** *Value Health* 2011 May; 14(3):A64-A5.

Vichinsky E, Pakbaz Z, Onyekwere O, et al. **Patient-reported outcomes of deferasirox (Exjade, ICL670) versus deferoxamine in sickle cell disease patients with transfusional hemosiderosis. Substudy of a randomized open-label phase II trial.** *Acta Haematol* 2008;119(3):133-41.

Weatherall J, Barnes N, Brown C, et al. **Future characteristics of bypassing agents to improve care of hemophilia inhibitor patients: an economic and health-related quality of life perspective.** *Expert Rev Pharmacoecon Outcomes Res* 2011 Aug;11(4):411-4.

### Immune system diseases

Jansen JP, O'Sullivan AK, Lugtenburg E, et al. **Economic evaluation of posaconazole versus fluconazole prophylaxis in patients with graft-versus-host disease (GVHD) in the Netherlands.** *Ann Hematol* 2010 Sep;89(9):919-26.

### Infections

Arnould B, Benmedjahed K, Gallais JL, et al. **The impact of herpes zoster and subsequent chronic pain on patients' daily lives.** *J Public Health* 2010; In press

Cella D, Gilet H, Viala-Danten M, et al. **Effects of etravirine versus placebo on health-related quality of life in treatment-experienced HIV patients as measured by the Functional Assessment of Human Immunodeficiency virus infection (FAHI) questionnaire in the DUET trials.** *HIV Clin Trials* 2010 January-February;11(1): 18-27.

Chevat C, Viala-Danten M, Dias-Barbosa C, et al. **Development and psychometric validation of a self-administered questionnaire assessing the acceptance of influenza vaccination: the Vaccinees' Perception of Injection (VAPI®) questionnaire.** *Health Qual Life Outcomes* 2009 March 4;7: 21.

Jansen JP, Kumar R, Carmeli Y. **Cost-Effectiveness evaluation of ertapenem versus piperacillin/tazobactam in the treatment of complicated intraabdominal infections accounting for antibiotic resistance.** *Value Health* 2009;12(2):234-44.

de Peuter MA, Littlewood KJ, Annemans L, et al. **Cost-effectiveness of catch-up programs in human papillomavirus vaccination.** *Expert Rev Vaccines* 2010 Oct;9(10):1187-201.

Hillemanns P, Breugelmanns JG, Giesecking F, et al. **Estimation of the incidence of genital warts and the cost of illness in Germany: a cross-sectional study.** *BMC Infect Dis* 2008 Jun 2;8:76.

Regnault A, Marfatia S, Louie M, et al. **Satisfactory cross-cultural validity of the ACTG symptom distress module in HIV-1-infected antiretroviral-naive patients.** *Clin Trials* 2009 December;6(6):574-84.

Reygrobelle C, Viala-Danten M, Meunier J, et al. **Perception and acceptance of intradermal influenza vaccination: Patient reported outcomes from phase 3 clinical trials.** *Hum Vaccin* 2010 April;6(4): 336-45.

## Peer Reviewed Journals

Spire B, Arnould B, Barbier F, et al. **Simplification and first validation of a short battery of patient questionnaires for clinical management of HIV-infected patients: the HIV-SQUAD (Symptom Quality of life ADherence) questionnaire®.** *HIV Clin Trials* 2009 July-August;10(4):215-32.

Viala-Danten M, Dubois D, Gilet H, et al. **Psychometric evaluation of the Functional Assessment of HIV Infection (FAHI) questionnaire and its usefulness in clinical trials.** *Qual Life Res* 2010 October;19(8):1215-27.

### Metabolic diseases

Arbuckle RA, Humphrey L, Vardeva K, et al. **Psychometric evaluation of the Diabetes Symptom Checklist-Revised (DSC-R) — a measure of symptom distress.** *Value Health* 2009 November;12(8): 1168-75.

Dias Barbosa C, Arnould B, Gruenberger JB, Schwarz P. **Considering the patient perspective for assessing the outcomes of diabetes lifestyle modification programmes: what should we measure, and how?** *The British Journal of Diabetes & Vascular Disease.* 2011;187-192.

Gilet H, Chachuat A, Viala-Danten M, et al. **Application of the disease-specific Quality of Life Assessment of Growth Hormone Deficiency in Adults (QoL-AGHDA) questionnaire in a general population: results from a French panel study.** *Value Health* 2010 June-July;13(4): 495-500.

Jansen JP, Kumar R, Carmeli Y. **Accounting for the development of antibacterial resistance in the cost effectiveness of ertapenem versus piperacillin/tazobactam in the treatment of diabetic foot infections in the UK.** *Pharmacoeconomics* 2009;27(12):1045-56.

Viala-Danten M, Martin S, Guillemin I, et al. **Evaluation of the reliability and validity of the Medical Outcomes Study sleep scale in patients with painful diabetic peripheral neuropathy during an international clinical trial.** *Health Qual Life Outcomes* 2008 December 17;6:113.

Yi Y, Philips Z, Bergman G, et al. **Economic models in type 2 diabetes.** *Curr Med Res Opin* 2010 September;26(9):2105-18.

### Musculoskeletal diseases

Arnold LM, Crofford LJ, Mease PJ, et al. **Patient perspectives on the impact of fibromyalgia.** *Patient Educ Couns* 2008 October;73(1):114-20.

Assink N, Bergman GJ, Knoester B, et al. **Assessment of the cervical range of motion over time, differences between results of the Flock of Birds and the EDI-320: a comparison between an electromagnetic tracking system and an electronic inclinometer.** *Man Ther* 2008 Oct;13(5):450-5.

Bergman GJ, Fan T, McFetridge JT, et al. **Efficacy of vitamin D3 supplementation in preventing fractures in elderly women: a meta-analysis.** *Curr Med Res Opin* 2010 May;26(5):1193-201.

Bergman GJ, Hochberg MC, Boers M, et al. **Indirect comparison of tocilizumab and other biologic agents in patients with rheumatoid arthritis and inadequate response to disease-modifying antirheumatic drugs.** *Semin Arthritis Rheum* 2010 Jun;39(6):425-41.

Bergman GJ, Winter JC, van Tulder MW, et al. **Manipulative therapy in addition to usual medical care accelerates recovery of shoulder complaints at higher costs: economic outcomes of a randomized trial.** *BMC Musculoskelet Disord* 2010 Sep 6;11:200.

Bergman GJ, Winters JC, Groenier KH, et al. **Manipulative therapy in addition to usual care for patients with shoulder complaints: results of physical examination outcomes in a randomized controlled trial.** *J Manipulative Physiol Ther* 2010 Feb;33(2):96-101.

## Peer Reviewed Journals

- Breuil V, Cortet B, Cotté F, et al. **Validation of the adherence evaluation of osteoporosis treatment (ADEOS) questionnaire for osteoporotic post-menopausal women.** *Osteoporos Int* 2011 April.
- Evans C, Chiou C, Fitzgerald K, Evans W, Ferrell B, Dale W, et al. **Development of a new patient-reported outcome measure in sarcopenia.** *JAMDA* 2011 March;226-33.
- Humphrey L, Arbuckle R, Mease P, et al. **Fatigue in fibromyalgia: a conceptual model informed by patient interviews.** *BMC Musculoskelet Disord* 2010 September 20;11(1):216.
- Jansen JP, Bergman GJ, Huels J, et al. **Prevention of vertebral fractures in osteoporosis: mixed treatment comparison of bisphosphonate therapies.** *Curr Med Res Opin* 2009 Aug;25(8):1861-8.
- Jansen JP, Bergman GJ, Huels J, et al. **The efficacy of bisphosphonates in the prevention of vertebral, hip, and nonvertebral-nonhip fractures in osteoporosis: a network meta-analysis.** *Semin Arthritis Rheum* 2010 Sep 7. [Epub ahead of print].
- Jansen JP, Gaugris S, Bergman G, et al. **Cost-effectiveness of a fixed dose combination of alendronate and cholecalciferol in the treatment and prevention of osteoporosis in the United Kingdom and The Netherlands.** *Curr Med Res Opin* 2008 Mar;24(3):671-84.
- Jansen JP, Gaugris S, Choy EH, et al. **Cost effectiveness of etoricoxib versus celecoxib and non-selective NSAIDs in the treatment of ankylosing spondylitis.** *Pharmacoeconomics* 2010 Apr 1;28(4):323-44.
- Nomden JG, Slagters AJ, Bergman GJ, et al. **Interobserver reliability of physical examination of shoulder girdle.** *Man Ther* 2009 Apr;14(2):152-9.
- Zlateva G, Diazaraque R, Viala-Danten M, et al. **Burden of anemia in patients with osteoarthritis and rheumatoid arthritis in French secondary care.** *BMC Geriatr* 2010 August 26;10(59).

### Nutrition

- Guyonnet D, Chassany O, Picard C, et al. **Perceived subject outcomes and impact on health-related quality of life associated with diet using the new Food Benefits Assessment (FBA) questionnaire: development and psychometric validation.** *Public Health Nutr* 2008 November;11(11):1163-72.
- Rofail D, Colligs A, Abetz L, et al. **Factors contributing to the success of folic acid public health campaigns.** *Public Health Advance Access* 2011 July;33(3):1-10.
- Yi Y, Lindemann M, Colligs A, et al. **Economic burden of neural tube defects and impact of prevention with folic acid: a literature review.** *Eur J Pediatr* 2011 May.

### Paediatrics

- Arbuckle R, Abetz L, Durmer JS, et al. **Development of the Pediatric Restless Legs Syndrome Severity Scale (P-RLS-SS): a patient-reported outcome measure of pediatric RLS symptoms and impact.** *Sleep Med* 2010 October;11(9):897-906.
- Cappelleri JC, Gerber RA, Quattrin T, et al. **Development and validation of the WEll-being and Satisfaction of CAREgivers of Children with Diabetes Questionnaire (WE-CARE).** *Health Qual Life Outcomes* 2008 January 18;6:3.
- Picchietti DL, Arbuckle RA, Abetz L, et al. **Pediatric Restless Legs Syndrome: Analysis of symptom descriptions and drawings.** *J Child Neurol* 2011 June.
- Yi Y, Lindemann M, Colligs A, et al. **Economic burden of neural tube defects and impact of prevention with folic acid: a literature review.** *Eur J Pediatr* 2011 May.

## Peer Reviewed Journals

### Respiratory tract diseases

- Aguilaniu B, Gonzalez-Bermejo J, Regnault A, Barbosa CD, Arnould B, Mueser M, et al. **Disability related to COPD tool (DIRECT): towards an assessment of COPD-related disability in routine practice.** *Int J Chron Obstruct Pulmon Dis*. 2011;6:387-398.
- Crawford B, Stanford R, Wong A, et al. **Development of a questionnaire to assess experience and preference of intranasal corticosteroids in patients with allergic rhinitis.** *Dove Medical Press* 2011 June;119-26.
- Crawford B, Stanford R, Wong A, et al. **Psychometric validation of the experience with allergic rhinitis nasal spray questionnaire.** *Dove Medical Press* 2011 June;127-33.
- Cope S, Capkun-Niggli G, Gale R, et al. **Comparative efficacy of indacaterol 150 µg and 300 µg versus fixed-dose combinations of formoterol + budesonide or salmeterol + fluticasone for the treatment of chronic obstructive pulmonary disease-a network meta-analysis.** *Int J Chron Obstruct Pulmon Dis* 2011 June;6:329-44.
- Perez T, Arnould B, Grosbois JM, et al. **Validity, reliability, and responsiveness of a new short Visual Simplified Respiratory Questionnaire (VSRQ) for health-related quality of life assessment in chronic obstructive pulmonary disease.** *Int J Chron Obstruct Pulmon Dis* 2009;4:9-18.

### Skin diseases

- Arbuckle R, Clark M, Harness J, et al. **Item reduction and psychometric validation of the Oily Skin Self Assessment Scale (OSSAS) and the Oily Skin Impact Scale (OSIS).** *Value Health* 2009 March 10. [Epub ahead of print].
- Arbuckle R, Atkinson MJ, Clark M, et al. **Patient experiences with oily skin: the qualitative development of content for two new patient reported outcome questionnaires.** *Health Qual Life Outcomes* 2008;6:80.

### Urogenital diseases

- Brubaker L, Khullar V, Piault E, et al. **Goal attainment scaling in patients with lower urinary tract symptoms: development and pilot testing of the Self-Assessment Goal Achievement (SAGA) questionnaire.** *Intl Urogynecol J* 2011 March; 22(8):937-46.
- Chevret-Méasson M, Cuzin B, Levrat F, et al. **The Index of Sexual Life questionnaire: a unique and valid tool to evaluate sexual quality of life and satisfaction of female partners of men with erectile dysfunction.** *PRO Newsletter* 2009;42:9-11.
- Chevret-Méasson M, Lavallée E, Troy S, et al. **Improvement in quality of sexual life in female partners of men with erectile dysfunction treated with sildenafil citrate: findings of the Index of Sexual Life (ISL) in a couple study.** *J Sex Med* 2009 March;6(3):761-9.
- Haab F, Richard F, Amarenco G, et al. **Comprehensive evaluation of bladder and urethral dysfunction symptoms: development and psychometric validation of the Urinary Symptom Profile (USP) questionnaire.** *Urology* 2008 April;71(4):646-56.
- Lasch KE, Evans CJ, Schatell D. **A qualitative analysis of patient-reported symptoms of anemia.** *Nephrol Nurs J* 2009 Nov-Dec 36(6):621-4, 631-2; quiz 633.

## Peer Reviewed Journals

### Womens health

Breuil V, Cortet B, Cotté F, et al. **Validation of the adherence evaluation of osteoporosis treatment (ADEOS) questionnaire for osteoporotic post-menopausal women.** *Osteoporos Int* 2011 April.

### Methodology

Fleurence RL, Naci H, Jansen JP. **The critical role of observational evidence in comparative effectiveness research.** *Health Aff (Millwood)* 2010 Oct;29(10):1826-33.

Hahn SR, Park J, Skinner EP, et al. **Development of the ASK-20 adherence barrier survey.** *Curr Med Res Opin* 2008 July;24(7):2127-38.

Jansen JP, Crawford B, Bergman G, et al. **Bayesian meta-analysis of multiple treatment comparisons: an introduction to mixed treatment comparisons.** *Value Health* 2008 Sep-Oct;11(5):956-64.

Jansen J, Fleurence R, Devine B, et al. **Interpreting indirect treatment comparisons and network meta-analysis for health-care decision making: report of the ISPOR task force on indirect treatment comparisons good research practices: Part 1.** *Elsevier* 2011 June;14(4):417-28.

Lasch KE, Marquis P, Vigneux M, et al. **PRO development: rigorous qualitative research as the crucial foundation.** *Qual Life Res* 2010 Oct;19(8):1087-96.

Marquis P, Caron M, Emery MP, et al. **The role of health-related quality of life data in the drug approval processes in the US and Europe A review of guidance documents and authorizations of medicinal products from 2006 to 2010.** *Pharm Med* 2011 June;25(3):148-60.

McGrath C, Rofail D, Gargon E, et al. **Using qualitative methods to inform the trade-off between content validity and consistency in utility assessment: the example of type 2 diabetes and Alzheimer's disease.** *Health Qual Life Outcomes* 2010 February 12;8:23.

Ouwens M, Philips Z, Jansen J. **Network meta-analysis of parametric survival curves.** *Research Synthesis Methods* 2011 March; 1 (3-4): 258-71.

## Conference oral presentations

### Cardiovascular diseases

Regnault A, Carita P, Gilet H, et al. **[Structural equation modelling of patient satisfaction towards their anticoagulant treatment] Modélisation par équations structurelles de la satisfaction des patients vis-à-vis de leur traitement anticoagulant.** Modèles et Apprentissage en Sciences Humaines et Sociales, Toulouse, France, 8-9 June 2009.

### Central nervous system / Mental disorders

Lasch K, Joish V, Zhu Y, et al. **Improved sleep impact in patients with major depressive disorder treated with zolpidem tartrate extended-release in combination with escitalopram.** Associated Professional Sleep Societies 22<sup>nd</sup> Annual Meeting, Baltimore, USA, 9-12 June 2008.

Regnault A, Gilet H, Meerding WJ, et al. **Methodological challenges for the evaluation of patient-reported screening tools: Example of a neuropathic pain screening tool.** 31<sup>st</sup> Annual Conference of the International Society for Clinical Biostatistics, Montpellier, France, 29 August – 2 September 2010.

### Gastrointestinal diseases

Carson R, Arbuckle R, Abetz L, et al. **The symptoms of irritable bowel syndrome with constipation (IBS-C): results of qualitative interviews with children and their parents.** ISOQOL 17<sup>th</sup> Annual Conference, London, UK, 27-30 October 2010.

### Musculoskeletal diseases

Legrand E, Breuil V, Cortet B, et al. **[Development and validation of the “Adherence in Osteoporosis” (ADEOS) questionnaire, an instrument evaluating treatment adherence in osteoporosis, for use clinical practice.] Développement et validation du questionnaire «Adhésion et Ostéoporose» (ADEOS), un instrument d'évaluation de l'adhésion des patientes au traitement de l'ostéoporose utilisable en pratique médicale courante.** 22<sup>ème</sup> Congrès de la Société Française de Rhumatologie, 28 November-2 December 2009, Paris, France.

Mease P, Humphrey L, Arbuckle R, et al. **Fibromyalgia fatigue – development of a conceptual model based on qualitative patient interviews.** ISPOR 12<sup>th</sup> Annual European Congress, Paris, France, 24-27 October 2009.

Mease P, Humphrey L, Arbuckle R, et al. **Fibromyalgia Fatigue – Development of a conceptual model based on qualitative patient interviews.** ISPOR 12<sup>th</sup> Annual European Congress, Paris, France, 24-27 October 2009.

Regnault A, Arnould B, Cortet B, et al. **Prediction of treatment discontinuation of osteoporotic patients using ADEOS score.** European League against Rheumatism (EULAR) congress; Rome, Italy 16-19 June 2010.

## Conference oral presentations

### Respiratory tract diseases

Gonzalez-Bermejo J, Aguilaniu B, Mueser M, et al. **[Validation of the “COPD and daily activities” questionnaire , a short questionnaire evaluating handicap of patients with COPD.] Validation du questionnaire BPCO et Activités quotidiennes, un questionnaire court d'évaluation du handicap des patients BPCO.** 14<sup>ème</sup> congrès de Pneumologie de Langue Française, Marseille, France, 29 January – 1 February 2010.

### Urogenital diseases

Rofail D, Abetz L, Lindermann M, et al. **Symptoms and impact of premenstrual dysphoric disorder (PMDD): concepts and measurement.** ISPOR 12<sup>th</sup> Annual European Congress, Paris, France, 24-27 October 2009.

### Methodology

Arbuckle R, Abetz L, Carson R, et al. **An introduction to paediatric patient-reported outcomes and paediatric clinical trial design.** ISOQOL 17<sup>th</sup> Annual Conference, London, UK, 27-30 October 2010.

Lasch K, Marquis P, Vigneux M, et al. **What patients say vs. what patients mean: qualitative research in PRO development.** ISPOR 13<sup>th</sup> Annual International Meeting, Toronto, Canada, 3-7 May 2008.

McGrath C, Rofail D, Abetz L. **Content validity of utility assessment in type II diabetes and Alzheimer's disease.** ISOQOL 17<sup>th</sup> Annual Conference, London, UK, 27-30 October 2010.

Mear I, Conway K, Regnault A, et al. **Similarities and differences in the expression of symptoms across countries: the translations of the PGI-SYM 20.** ISOQOL 17<sup>th</sup> Annual Conference, London, UK, 27-30 October 2010.

Regnault A, Mear I, Mollon P, et al. **Addressing cross-cultural issues with Patient-Reported Outcomes assessments to strengthen evidence obtained in an international context.** ISPOR 11<sup>th</sup> Annual European Congress, Athens, Greece, 8-11 November 2008.

Regnault A, Siliman G, Kerstens R, et al. **Development of symptom measures reflecting the relative impact of symptoms on health-related quality of life: application to chronic constipation.** ISOQOL 17<sup>th</sup> Annual Conference, London, UK, 27-30 October 2010.

Rofail D, Regnault A, Baladi JF, et al. **Assessing treatment satisfaction during a product's lifecycle to facilitate market access: definitions, frameworks, and measurement.** ISPOR 12<sup>th</sup> Annual European Congress, Paris, France, 24-27 October 2009.

Symonds T, Regnault A, Carson R, et al. **The challenges of symptom assessment in clinical research: illustrations in gastrointestinal conditions.** ISOQOL 17<sup>th</sup> Annual Conference, London, UK, 27-30 October 2010.

## Posters

## Cancer

- De Jong F, Viala M, van Herwaarden R, et al. **Psychometric validation of a patient questionnaire evaluating satisfaction with a darbepoetin alpha pre-filled device for self-injection (Aranesp® Sureclick™ device) and a home-service (2care® service) in chemotherapy-induced anaemic cancer patients.** ISPOR 15<sup>th</sup> Annual International Meeting, Atlanta, GA, USA, May 15-19 2010.
- Dhawan R, Meunier J, Regnault A, et al. **Impact of complete response on health-related quality of life in newly diagnosed multiple myeloma patients: results from the VISTA trial patients.** 12<sup>th</sup> International Multiple Myeloma Workshop, Washington DC, USA, 26 February – 1 March 2009.
- Dhawan R, Robinson D, Meunier J, et al. **Sustained Health-Related Quality of Life (HRQoL) improvement in patients with newly diagnosed multiple myeloma treated with Bortezomib / Melphalan / Prednisone (VMP) versus MP: Results from the VISTA trial.** 51<sup>st</sup> Annual meeting of the American Society of Hematology (ASH); 5-8 December 2009.
- Hudgens S. **Quality of life in small cell lung cancer: Results of an open-label phase III clinical trial.** 11-8-2011. ISPOR 14<sup>th</sup> Annual European Congress, 5-8 November 2011.
- Jansen J, Zeppetella G, Vissers D, et al. **The efficacy of formulations of oral morphine in the treatment of breakthrough cancer pain (BTCP).** European Federation of Chapters of the International Association for the Study of Pain (EFIC) 6<sup>th</sup> triennial congress. Pain in Europe VI, Lisbon, Portugal, 9 sept 2009.
- Lasch K, Marquis P, Zeytoonjian A, et al. **Results of the patient reported outcomes of fatigue in cancer consortium study: patients define cancer-related fatigue.** 2<sup>nd</sup> International Cancer Fatigue Symposium, Montreal, Canada, 3-4 October 2010.
- Meunier J, Regnault A, Robinson DJ, et al. **Impact of tumor response on health-related quality of life (HRQoL) in newly diagnosed multiple myeloma patients treated with VELCADE/melphalan/prednisone (V-MP): results from the VISTA trial.** ISPOR 12<sup>th</sup> Annual European Congress, Paris, France, 24-27 October 2009.
- Oyee J, Thomson A, Sendersky V, et al. **The budget impact of intranasal fentanyl spray (Instanyl®) in the treatment of breakthrough pain (BTP) in patients with cancer in the UK.** 8<sup>th</sup> Palliative Care Congress, Bournemouth, UK, 10<sup>th</sup> March 2010.
- Regnault A, Gater A, Battersby C, et al. **Confirmation of brief pain inventory short form (BPI-SF) 'worst pain' item cut-point for the assessment of pain progression in castration-resistant prostate cancer (CRPC).** ISPOR 13<sup>th</sup> Annual European Congress, Prague, Czech Republic, 6-9 November 2010.
- Rofail D, Abetz L, Caron M, et al. **Oncology patient-reported claims: maximising the chance for success.** ISPOR 12<sup>th</sup> Annual European Congress, Paris, France, 24-27 October 2009.
- Scott J, Piau E, Jernigan K. **Leveraging patient reported outcomes to define fatigue in cancer.** ISPOR 14<sup>th</sup> Annual Meeting, Orlando, USA, 16-20 May 2009.
- Stam W, Vissers D, Lenre M, et al. **An economic evaluation of fast-acting opioids for the treatment of breakthrough pain in cancer patients in Sweden.** European Federation of Chapters of the International Association for the Study of Pain (EFIC) 6<sup>th</sup> triennial Congress, Lisbon, Portugal, 9-12 September 2009.

## Posters

Yi Y, Cope S, Chouaid C, et al. **A mixed treatment comparison of bevacizumab-based therapies relative to doublet platinum-based and non-platinum-based chemotherapy combinations in progression free survival for the treatment of first-line advanced or metastatic Non-Small Cell Lung Cancer (NSCLC).** Chicago Multidisciplinary Symposium in Thoracic Oncology, Chicago, USA, 9-11 December 2010.

Yi Y, Chouaid C, Vergnenegre A, et al. **Mixed treatment comparison of bevacizumab-based therapies relative to doublet-chemotherapy combinations to estimate the relative efficacy in progression free survival for treatment of first-line advanced or metastatic non-small cell lung cancer (NSCLC).** ISPOR 13<sup>th</sup> Annual European Congress, Prague, Czech Republic, 6-9 November 2010.

### Cardiovascular diseases

Hudgens S. **Validation of a Patient-Reported Outcome (PRO) measure and a Clinician-Reported Outcome (CRO) Measure to assess satisfaction and preference with pharmacological stress agents for Single Photon Emission Computed Tomography (SPECT) Myocardial Perfusion Imaging (MPI).** ISPOR 14<sup>th</sup> Annual European Congress, 5-8 November 2011.

Hudgens S. **Evaluation of the measurement properties of the antihypertensive adherence survey.** ISPOR 14<sup>th</sup> Annual European Congress, 5-8 November 2011.

Prins M, Leguet P, Gilet H, et al. **Convenience of and satisfaction with the new long-acting anticoagulant idraparinux (IDRA) vs. vitamin K antagonist (VKA) in patients with deep venous thrombosis (DVT), pulmonary embolism (PE) and atrial fibrillation (AF).** ISTH, International Society on Thrombosis and Haemostasis, Boston, USA 11-16 July 2009.

Prins M, Leguet P, Gilet H, et al. **Convenience of the new long-acting anticoagulant idraparinux versus vitamin K antagonist (VKA) in patients with atrial fibrillation (AF).** ISPOR 13<sup>th</sup> Annual International meeting, Toronto, Canada, 3-7 May 2008.

Regnault A, Gilet H, Carita P, et al. **Exploring patients' satisfaction with anticoagulant treatment by applying Structural Equation Models to the perception of AntiCoagulant Treatment Questionnaire (PACT-Q).** ISPOR 12<sup>th</sup> Annual European Congress, Paris, France, 24-27 October 2009.

### Central nervous system / Mental disorders

Guillemin I, Lam A, Richarz U, et al. **Assessing the value of 24-hour chronic pain control from the patient perspective: do existing patient-reported outcome instruments adequately cover the relevant concepts related to 24-hour chronic pain control?** ISPOR 11<sup>th</sup> Annual European Congress, Athens, Greece, 8-11 November 2008.

Rofail D, Kitchen H, Heron L, et al. **Cognitive impairment associated with schizophrenia: the humanistic and economic burden.** American Neurological Association 135<sup>th</sup> Annual Meeting, San Francisco, USA, 12-15 September 2010.

## Posters

### Eye diseases

- Abetz L, Chalmers R, Begley C, et al. **The Impact of Dry Eye on Everyday Life (IDEEL) questionnaire: saturation, reliability, validity and discriminative ability compared to generic measures.** ISPOR, 13<sup>th</sup> Annual Meeting, Toronto, Canada, 3-7 May 2008.
- Arnould B, Benmedjahed K, Berdeaux G, et al. **Patients' perception of life free of glasses after cataract surgery: development of the Freedom from Glasses Value Scale (FGVS<sup>®</sup>).** ISPOR 13<sup>th</sup> Annual International Meeting, Toronto, Canada, 3-7 May 2008.
- Fitzgerald K. **Patient perspective of the burden of RVO: a qualitative understanding of vision related functioning and the NEI VFQ-25.** ARVO Annual Meeting, Reducing Disparities in Eye Disease and Treatment, Fort Lauderdale, Florida, 3-7 May 2009.
- Guillemin I, Arnould B. **A review of patient-reported outcome instruments measuring the impact of dry eye on health-related quality of life.** 6<sup>th</sup> International Conference on the Tear Film & Ocular Surface Basic Science and Clinical Relevance (TFOS), Florence, Italy, 22-25 September 2010.
- Regnault A, Viala-Danten M, Arnould B, et al. **Identifying non compliant glaucoma patients using the EDSQ, a questionnaire measuring satisfaction and compliance of glaucoma treatment.** ISPOR 11<sup>th</sup> Annual European Congress, Athens, Greece, 8-11 November 2008.
- Regnault A, Viala-Danten M, Vigneux M, et al. **Scoring and psychometric properties of the Eye-Drop Satisfaction Questionnaire (EDSQ).** ISPOR 11<sup>th</sup> Annual European Congress, Athens, Greece, 8-11 November 2008.
- Tugaut B, Meunier J, Viala-Danten M, et al. **Vision-Related Quality of life instruments (QoL) after refractive cataract surgery.** ISPOR 13<sup>th</sup> Annual European Congress, Prague, Czech Republic, 6-9 November 2010.

### Gastrointestinal diseases

- Arbuckle R, Lewis BE, Carson R, et al. **Child and parent reports of symptoms of irritable bowel syndrome with constipation (IBS-C): results of qualitative interviews.** ISPOR 13<sup>th</sup> Annual European Congress, Prague, Czech Republic, 6-9 November 2010.
- Arnould B, Marrel A, Marant C, et al. **Development of a questionnaire to evaluate treatment satisfaction of patients with severe Crohn's disease: qualitative steps.** ISPOR 12<sup>th</sup> Annual European Congress, Paris, France, 24-27 October 2009.
- Regnault A, Siliman G, Dubois D, et al. **Development of symptom indices using formative structural equation models: application to the PAC-SYM questionnaire.** 31<sup>st</sup> Annual Conference of the International Society for Clinical Biostatistics, Montpellier, France, 29 August – 2 September 2010.

## Posters

### Infections

- Carroll S, Gater A, Abetz L, et al. **Herpes zoster and post-herpetic neuralgia: considerations for a prospective, cross-sectional, patient reported outcomes study.** ISPOR 13<sup>th</sup> Annual European Congress, Prague, Czech Republic, 6-9 November 2010.
- Gater A, Carroll S, Abetz L, et al. **Quantifying the patient-reported burden of herpes zoster and post-herpetic neuralgia in the UK: practical considerations.** ISOQOL 17<sup>th</sup> Annual Conference, London, UK, 27-30 October 2010.
- Gilet H, Martin S, Viala-Danten M. **Psychometric evaluation of the Functional Assessment of HIV Infection (FAHI) questionnaire in two clinical programmes.** ISPOR 12<sup>th</sup> Annual European Congress, Paris, France, 24-27 October 2009.
- Littlewood KJ, Sauboin C, Ouwens M. **Cost-effectiveness of mass varicella vaccination in France: economic consequences of an intensive vaccination programme.** ISPOR 12<sup>th</sup> Annual European Congress, Paris, France, 24-27 October 2009.
- Littlewood KJ, Vissers D, Ouwens M, et al. **Cost-effectiveness of mass vaccination for varicella in France with MMRV versus MMR.** ISPOR 11<sup>th</sup> Annual European Congress, Athens, Greece, 8-11 November 2008.
- Meunier J, Reygrobellet C, Weber F, et al. **Perception and acceptance of intradermal influenza vaccine measured by the vaccinee's perception of injection (VAPI®) questionnaire.** ISPOR 12<sup>th</sup> Annual European Congress, Paris, France, 24-27 October 2009.
- Ouwens M, Littlewood K, Boelle PY. **Mass vaccination impact on varicella cases in France: model-based comparison using empirical versus traditional contact matrices.** ESPID (European Society for Paediatric Infectious Diseases), 27<sup>th</sup> Annual Meeting, Brussels, Belgium, 9-13 June 2009.
- Ouwens M, Littlewood K, Sauboin C, et al. **Impact of MMRV mass vaccination with or without a catch up programme on the incidence of varicella complications in France.** ISPOR 13<sup>th</sup> Annual European Congress, Prague, Czech Republic, 6-9 November 2010.
- Regnault A, Marfatia S, Louie M, et al. **Assessment of the cross-cultural validity of an HIV symptom distress module in an international HIV clinical trial.** ISPOR 13<sup>th</sup> Annual International Meeting, Toronto, Canada, 3-7 May 2008.
- Vissers D, Ouwens M, Littlewood KJ, et al. **Impact of mass vaccination with MMRV versus MMR in France on the epidemiology of varicella and herpes zoster, using a dynamic transmission model.** ISPOR 11<sup>th</sup> Annual European Congress, Athens, Greece, 8-11 November 2008.

### Metabolic diseases

- Bettioli E, Marant C, Burlina A, et al. **International development of disease-specific questionnaires to assess the impact of phenylketonuria and its treatment on daily life: qualitative steps.** SSIEM Annual symposium, Istanbul, Turkey, 31 August-3 September 2010.
- Yi Y, Bergman G, Burslem K, et al. **Critical review of economic models in type 2 diabetes.** ISPOR 12<sup>th</sup> Annual European Congress, Paris, France, 24-27 October 2009.

## Posters

## Musculoskeletal diseases

- Alègre P, Arnould B, Spizak C, et al. **Use of qualitative research to identify determinants of persistence for anti-osteoporotic treatments.** ISPOR 13<sup>th</sup> Annual European Congress, Prague, Czech Republic, 6-9 November 2010.
- Arnould B, Benmedjahed K, Barnes N, et al. **Qualitative steps for the development of a questionnaire assessing the burden of fibromyalgia on patients' daily lives.** ISPOR 11<sup>th</sup> Annual European Congress, Athens, Greece, 8-11 November 2008.
- Baron R, Arnould B, Alegre C, et al. **Factors to help primary care physicians detecting fibromyalgia in routine practice.** 6<sup>th</sup> Congress of the European Federation of IASP<sup>®</sup> Chapters (EFIC), Lisbon, Portugal, 9-12 September 2009.
- Breuil V, Cortet B, Legrand E, et al. **[Prescription renewal, doctor's judgment and patient statements: three complementary perspectives for evaluating adherence in patients treated for osteoporosis.] Le renouvellement des prescriptions, le jugement du médecin, les déclarations des patientes: trois perspectives complémentaires pour l'évaluation de l'adhésion des patientes pour leur traitement de l'ostéoporose.** 22<sup>ème</sup> Congrès de la Société Française de Rhumatologie, Paris, France, 28 November-2 December 2009.
- Breuil V, Cortet B, Legrand E, et al. **Development and content validation of a new adherence questionnaire in osteoporotic post-menopausal women: ADherence Evaluation of OSteoporosis treatment (ADEOS) questionnaire.** 31<sup>st</sup> annual meeting of the American Society for Bone and Mineral Research (ASBMR), Denver, CO, US, 11-15 September 2009.
- Carbonnel JA, Serra E, Spaeth M, et al. **[Development in four languages of a questionnaire evaluating the burden of fibromyalgia on the daily lives of patients: qualitative steps.] Développement en quatre langues d'un questionnaire évaluant le fardeau de la fibromyalgie sur la vie quotidienne des patients : étapes qualitatives.** 21<sup>ème</sup> Congrès Français de Rhumatologie, CNIT-Paris la Défense, 14-17 December 2008.
- Cortet B, Legrand E, Breuil V, et al. **Item reduction and validation of a new adherence questionnaire in osteoporotic post-menopausal women: the ADherence Evaluation of OSteoporosis treatment (ADEOS) questionnaire.** ISPOR 12<sup>th</sup> Annual European Congress, Paris, France , 24-27 October 2009.
- Cruccu G, Perrot S, Arnould B, et al. **Sensory symptoms in fibromyalgia patients suggest a nervous system involvement.** European Federation of Neurological Societies (EFNS), 13<sup>th</sup> annual conference, Florence, Italy, 12-15 September 2009.
- Dias-Barbosa C, Guillemin I, Perrot S, et al. **Development of a tool to help in the early detection of fibromyalgia in general practice in Europe.** ISPOR 12<sup>th</sup> Annual European Congress, Paris, France, 24-27 October 2009.

## Posters

- Margaux J, Perrot S, Arnould B, et al. **Factors to help primary care physicians detect fibromyalgia in routine practice.** 13<sup>th</sup> Belgian Congress of Rheumatology, Mechelen, Belgium, 23-25 September 2009.
- Pericleous L, Lebmeier M, Drost P, et al. **The cost-effectiveness of abatacept in combination with methotrexate for the treatment of patient with active rheumatoid arthritis after an inadequate response to methotrexate in the united kingdom.** ISPOR 13<sup>th</sup> Annual European Congress, Prague, Czech Republic, 6-9 November 2010.
- Roborel de Climens A, Cotté F, Dias-Barbosa C, et al. **The ADEOS questionnaire (ADherence Evaluation of OSteoporosis treatment): development of a specific tool to evaluate women's adherence to osteoporosis treatment.** ISPOR 11<sup>th</sup> Annual European Congress, Athens, Greece, 8-11 November 2008.
- Serra E, Perrot S, Guillemin I, et al. **Improving the diagnosis of fibromyalgia in Europe: identification of factors that aid in the detection of fibromyalgia.** ISPOR 11<sup>th</sup> Annual European Congress, Athens, Greece, 8-11 November 2008.
- Serra E, Spaeth M, Carbonnel JA, et al. **Content validity of the FibroMyalgia syndrome Burden Assessment (FMBA®).** ISPOR 12<sup>th</sup> Annual European Congress, Paris, France, 24-27 October 2009.

### Paediatrics

- Bright N, Maguire L, Arbuckle R A, et al. **Testing of a conceptual model of asthma in adolescents.** ISPOR 14<sup>th</sup> Annual European Congress, Madrid, Spain, November 5-8, 2011.
- Lapillonne A, Gournay V, Gouyon J, et al. **The Impact of Bronchiolitis Hospitalization Questionnaire: IBHQ® Development of a specific questionnaire assessing the impact on parents of an infant's bronchiolitis-related hospitalization.** ISPOR 14<sup>th</sup> Annual International Meeting, Orlando, USA, 16-20 May 2009.
- Picchietti D, Arbuckle R, Abetz L, et al. **Pediatric restless legs syndrome: Qualitative analysis of symptom descriptions and drawings.** 33<sup>rd</sup> Sleep Conference, San Antonio, USA, 5-9 June 2010.
- Viala-Danten M, Meunier J, Arnould B. **Development and psychometric validation of a new questionnaire measuring the impact of child gastroenteritis on parents.** ISPOR 11<sup>th</sup> Annual European Congress, Athens, Greece, 8-11 November 2008.
- Yi Y, Verdian L, Heyes A, et al. **A comparison of cost effectiveness of rufinamide with lamotrigine and topiramate in the adjunctive treatment of Lennox-Gastaut syndrome.** ISPOR 11<sup>th</sup> Annual European Congress, Athens, Greece, 8-11 November 2008.

## Posters

### Respiratory tract diseases

- Bright N, Maguire L, Arbuckle R A, et al. **Testing of a conceptual model of asthma in adolescents.** ISPOR 14th Annual European Congress, Madrid, Spain, November 5-8 2011.
- Gonzalez-Bermejo J, Similowski T, Granet G, et al. **[Evaluation of disability in clinical practice in patients with COPD using the COPD and ADL questionnaire] Evaluation du handicap des patients BPCO en pratique médicale courante à l'aide du questionnaire "BPCO et activités quotidiennes".** 13<sup>th</sup> Congrès de Pneumologie de Langue Française (CPLF), Lyon, France, 16-19 January 2009.
- Regnault A, Mueser Ruphin M, Dias-Barbosa C, et al. **Item selection and scoring definition of a disease-specific instrument to assess the handicap in Chronic Obstructive Pulmonary Disease (COPD) patients, for use in clinical routine practice.** ISPOR 12<sup>th</sup> Annual European Congress, Paris, France, 24-27 October 2009.
- Rudell K, Bonner N, Arbuckle R, et al. **How congruent are patient and clinician models of asthma control? Preliminary findings from a qualitative study.** ISPOR 11<sup>th</sup> Annual European Congress, Athens, Greece, 8-11 November 2008.
- Staniek V, Williams AE, Emery MP, et al. **Treatment satisfaction questionnaires in asthma and other chronic diseases.** ISPOR 13<sup>th</sup> annual international meeting, Toronto, Canada, 3-7 May 2008.

### Skin diseases

- Harness J, Draelos Z, Thiboutot D, et al. **Patient experiences with oily skin: the development of two new patient-reported outcomes questionnaires.** American Academy of Dermatology 67<sup>th</sup> annual meeting, San Francisco, USA, 6-10 March 2009.
- Mamolo C, Harness J, Arbuckle R, et al. **Psychometric validation of the Oily Skin Self Assessment Scale (OSSAS) and the Oily Skin Impact Scale (OSIS).** American Academy of Dermatology 67<sup>th</sup> annual meeting, San Francisco, USA, 6-10 March 2009.
- Marant C, Emery MP, Dias-Barbosa C, et al. **A disease model illustrating the impact of psoriasis on patients' lives.** ISPOR 11<sup>th</sup> Annual European Congress, Athens, Greece, 8-11 November 2008.
- Roborel de Climens A, Marant C, Arnould B, et al. **Development of an instrument mirroring patient and physician perception of psoriasis severity and treatment effect.** ISPOR 13<sup>th</sup> Annual European Congress, Prague, Czech Republic, 6-9 November 2010.

## Posters

### Urogenital diseases

- Abraham L, Arbuckle R, Bonner N, et al. **How do patients describe their symptoms of interstitial cystitis/painful bladder syndrome (IC/PBS)? Qualitative interviews with patients to support the development of a patient-reported symptom-based screener for IC/PBS.** ISPOR 12<sup>th</sup> Annual European Congress, Paris, France, 24-27 October 2009.
- Dubois D, Vandeplassche L, Tack J, et al. **Cumulative distribution curves of prucalopride treatment effects in severe chronic constipation.** 11<sup>th</sup> Annual European Congress of the International Society for Quality of Life Research, Montevideo, Uruguay, 22–25 October, 2008.
- Jansen J, Evans C, Guyot P, et al. **A review of the effect of epoetin alfa on exercise tolerance and physical functioning.** National Kidney Foundation spring meeting, Dallas, USA, 2-6 April 2008.
- Rofail D, Abetz L, Lindermann M, et al. **Symptoms and impact of premenstrual dysphoric disorder (PMDD): concepts and measurement.** ISPOR 12<sup>th</sup> Annual European Congress, Paris, France, 24-27 October 2009.

### Womens health

- Abraham L, Arbuckle R A, Dennerstein L, Humphrey L, Maguire L, Mirkin S, et al. **How Do Breast Pain and Breakthrough Bleeding Associated with Hormonal Treatments for Menopausal Symptoms Impact Post-menopausal Women's Lives: Qualitative Interviews with Post-menopausal Women in the USA, China, Mexico and Italy.** ISPOR 14<sup>th</sup> Annual European Congress, Madrid, Spain, November 5-8 2011.

## Posters

### Methodology

- Chretien S, Viala-Danten M, Van Ganse E, et al. **The missing piece between treatment experience and intention to persist: testing the internal consistency reliability and predictive validity of acceptability.** ISPOR 13<sup>th</sup> Annual European Congress, Prague, Czech Republic, 6-9 November 2010.
- Guyot P, Ouwens M. **The use of survival analyses for cost-effectiveness models: an evaluation of methods used in NICE appraisals.** ISPOR 12<sup>th</sup> Annual European Congress, Paris, France, 24-27 October 2009.
- Jansen J. **When are indirect treatment comparisons biased? A graphical explanation.** DIA Washington DC, USA, 23-24 March 2010.
- Jansen J. **Adjusted indirect treatment comparison of survival curves: an example with multiple myeloma treatments.** DIA Washington DC, USA, 23-24 March 2010.
- Lasch K, Mukherjee Bal V, Marquis P, et al. **Can we use clinical terms to describe symptoms for labeling claims?** DIA 47th Annual Drug Information Association Annual Meeting, 19-23 June 2011.
- Lebmeier M, Pericleous L, Guyot P, et al. **Indirect treatment comparison to compare efficacy in health assessment questionnaire (HAQ) score for biologic agents with methotrexate in patients with rheumatoid arthritis and active disease despite methotrexate therapy.** ISPOR 13<sup>th</sup> Annual European Congress, Prague, Czech Republic, 6-9 November 2010.
- Marant C, Longin J, Spizak C, et al. **What does acceptability mean for patients and how should it be measured? Qualitative steps for the development of a new measurement instrument for pharmacies: the “ACCEPT<sup>®</sup>” questionnaire.** ISPOR 11<sup>th</sup> Annual European Congress, Athens, Greece, 8-11 November 2008.
- Marant C, Spizak C, Longin J, et al. **Development of the ACCEPT<sup>®</sup> questionnaire to assess acceptability of long-term treatments: qualitative steps.** ISPOR 12<sup>th</sup> Annual European Congress, Paris, France, 24-27 October 2009.
- Marquis P, Caron M, Emery MP, et al. **The role of health-related quality of life data in the drug approval processes in the USA and Europe: a review of guidance documents and authorizations of medicinal products from 2006 to 2010.** ISPOR 15th Annual International Meeting, Baltimore, MD, USA, 21-25 May 2011.
- Ouwens M, Philips Z. **How to make use of available survival evidence in an indirect comparison.** ISPOR 12<sup>th</sup> Annual European Congress, Paris, France, 24-27 October 2009.
- Rofail D, Regnault A, Taylor F, et al. **Treatment satisfaction instruments for different purposes during a product's lifecycle - keeping the end in mind.** ISPOR 13<sup>th</sup> Annual European Congress, Prague, Czech Republic, 6-9 November 2010.
- Viala-Danten M, Regnault A, Berdeaux G. **The interpretation of patient-reported outcome data: a challenge for statisticians?** 31<sup>st</sup> Annual Conference of the International Society for Clinical Biostatisticians, Montpellier, France, 29 August – 2 September 2010.

Mapi Values is a global company with offices in the following locations:

**Mapi Values USA**

133 Portland Street  
Boston, MA 02114  
USA

T: +1 (617) 720-0001  
F: +1 (617) 720-0004

**Mapi Values UK**

Adelphi Mill, Bollington  
Macclesfield, Cheshire  
SK10 5JB, UK

T: +44 (0) 1625 576815  
F: +44 (0) 1625 577328

**Mapi Values France**

27, rue de la Villette  
69003 Lyon  
France

T: +33 (0) 4 72 13 66 62  
F: +33 (0) 4 72 13 51 40

**Mapi Values Netherlands**

De Molen 84  
3995 AX Houten  
The Netherlands

T: +31 (0) 30 636 697 63  
F: +31 (0) 30 636 697 70

**Mapi Values Asia**

Arco Tower 12F  
1-8-1 Shimomeguro  
Meguro-ku  
Tokyo 153-0064, Japan

T: +81 03 5436 2070  
F: +81 03 5436 2071

[www.mapivalues.com](http://www.mapivalues.com)